An FDA official has issued a memo citing reports of excessive sedation in some patients who received a long-acting, injectable form of Zyprexa, Eli Lilly and Co.'s blockbuster schizophrenia drug. The Indianapolis-based drugmaker says the formulation offers advantages that outweigh safety concerns, which it says "are manageable with appropriate labeling and risk-minimization activities."

Related Summaries